US ophthalmic drugs market set to pass $34bn by 2025
European Pharmaceutical Review | July 25, 2017
The US ophthalmic drugs market is set pass $34bn by 2025, fueled by an increasing incidence of eye diseases, according to a new report. Compound annual growth rate of 4.0% from 2017 to 2025 saw the value of the market rise from $24.4bn in 2016 to a predicted value of $34.3bn by 2025. Major market players across the US are upping investments in research to innovate on treatment methods and improve ophthalmic drugs action mechanisms with novel biological agents, according to the Transparency Market Research (TMR) report.